Lv2
128 积分 2025-10-12 加入
Replicative gaps in DNA damage tolerance, genome instability, and cancer therapy
17天前
已完结
Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer
1个月前
已关闭
#141 Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer
2个月前
已完结
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
3个月前
已完结
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
3个月前
已完结
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial
5个月前
已完结
JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials
5个月前
已关闭
Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy
6个月前
已完结
NCOG-37. Outcomes from online education focused on novel targeted therapies for IDH-mutant gliomas
6个月前
已完结